Drug Patent Watch
NOVEMBER 12, 2023
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending… The post AI-Driven Strategies: Pharma’s Answer to Patent Expirations appeared first on DrugPatentWatch - Make Better Decisions.
STAT
NOVEMBER 16, 2023
LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new phase of genetic medicine. The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
NOVEMBER 16, 2023
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
ALiEM - Pharm Pearls
NOVEMBER 17, 2023
A 4-year-old female with no significant past medical history is brought to the Emergency Department by her grandmother for concern for two days of progressive vaginal bleeding. The grandmother first noted blood in the patient’s underwear the previous morning when she was helping the patient wipe and she noticed it again prior to arrival, this time saturating the patient’s underwear.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The Pharmacist
NOVEMBER 15, 2023
The highly anticipated Pharmacy First common conditions service in England is set to launch at the end of January, it has been announced. The news comes as part of a series of announcements confirmed by NHS England (NHSE) and Community Pharmacy England (CPE) today, which also included updates on contraception and hypertension services. And CPE […] The post Breaking: Pharmacy First to launch end of January appeared first on The Pharmacist.
STAT
NOVEMBER 16, 2023
BAD RIVER RESERVATION, Wis. — Sunlight is streaming through holes in the walls of a disused, corrugated metal shack, revealing its modest insides: Dirt floors, stacks of two-by-fours, and a pile of Little Caesars pizza boxes under attack by a work crew on lunch break. This building is clearly not ready to be a home. But in the next 24 hours, it must become one.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
ALiEM - Pharm Pearls
NOVEMBER 13, 2023
A 57-year-old female college counselor living in the northeastern United States with no PMH presented for evaluation of rash, joint pain, and dyspnea for the past three weeks. The patient first noticed the rash on her upper back, describing it as being itchy. The rash then spread to her face, scalp, and thighs. Two weeks ago, she noticed swelling in her hands and had a gradual onset of dyspnea on exertion.
The Pharmacist
NOVEMBER 16, 2023
The first electronic prescription service (EPS) in Wales has launched today, allowing patients and healthcare professionals to benefit from ‘easier, safer and more efficient’ prescribing and dispensing, the Welsh Government has said. Instead of printing, signing and giving a patient a paper form to take to a pharmacy, GPs will be able to send the […] The post Wales launches first electronic prescription service appeared first on The Pharmacist.
STAT
NOVEMBER 14, 2023
A class action lawsuit was filed Tuesday against UnitedHealth Group and a subsidiary alleging that they are illegally using an algorithm to deny rehabilitation care to seriously ill patients, even though the companies know the algorithm has a high error rate. The class action suit, filed on behalf of deceased patients who had a UnitedHealthcare Medicare Advantage plan and their families by the California-based Clarkson Law Firm, follows the publication of a STAT investigation Tuesday.
PharmaVoice
NOVEMBER 13, 2023
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmExec
NOVEMBER 15, 2023
Defencath is indicated for the prevention and treatment of catheter-related bloodstream infections in adults with kidney failure administered chronic hemodialysis via a central venous catheter.
The Pharmacist
NOVEMBER 16, 2023
Community pharmacists will be able access and add to patient records currently maintained by GPs from January next year, in a bid to free up millions of GP appointments. The Government, NHS England and Community Pharmacy England said they agreed that the Pharmacy First scheme will launch on 31 January 2024, subject to the ‘appropriate digital […] The post Community pharmacists to gain greater access to GP record from January appeared first on The Pharmacist.
STAT
NOVEMBER 14, 2023
The nation’s largest health insurance company pressured its medical staff to cut off payments for seriously ill patients in lockstep with a computer algorithm’s calculations, denying rehabilitation care for older and disabled Americans as profits soared, a STAT investigation has found. UnitedHealth Group has repeatedly said its algorithm, which predicts how long patients will need to stay in rehab, is merely a guidepost for their recoveries.
PharmaVoice
NOVEMBER 15, 2023
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
Big Molecule Watch
NOVEMBER 16, 2023
Earlier today, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for their CRISPR/Cas9 gene therapy, CASGEVY (exagamglogene autotemcel), marking the world’s first regulatory approval for a CRISPR-based gene-edited therapy. CASGEVY is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR.
The Pharmacist
NOVEMBER 15, 2023
The Royal College of General Practitioners (RCGP) has called for pharmacist training and supervision to be resourced appropriately as the profession takes on more responsibility. This follows comments made by a GP panellist at the recent Royal Pharmaceutical Society (RPS) conference who suggested that training pharmacist prescribers was becoming a ‘burden’ on GPs tasked with […] The post Resource prescribing supervisors appropriately, calls RCGP appeared first on The Pharmacist.
STAT
NOVEMBER 15, 2023
The Food and Drug Administration granted marketing approval to a home test for chlamydia and gonorrhea on Wednesday, the first such authorization of a home test to detect the two most common sexually transmitted infections in this country. The marketing approval was granted to LetsGetChecked’s Simple 2 Test, which allows individuals to collect a sample at home that is then submitted to a laboratory for processing.
Pharma Times
NOVEMBER 17, 2023
The AI system will identify those most at risk and reduce pressure on the NHS - News - PharmaTimes
Drug Patent Watch
NOVEMBER 17, 2023
Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light… The post Navigating Legal Waters: Study Delves into Inequitable Conduct in Drug Patent Cases appeared first on DrugPatentWatch - Make Better Decisions.
The Pharmacist
NOVEMBER 13, 2023
Pharmacy minister Neil O’Brien has resigned from his post, saying that he wants to focus on constituency work and time with his family. This comes as other junior ministers, including former pharmacy minister and then minister for Health and Secondary Care Will Quince have also handed in their resignations. It follows a major cabinet shake-up, […] The post Pharmacy minister quits amid government shake-up appeared first on The Pharmacist.
STAT
NOVEMBER 13, 2023
The life expectancy of men in the U.S. is nearly six years shorter than that of women, according to new research published on Monday in JAMA Internal Medicine. At least partially as a consequence of over 1 million Covid-19 deaths, life expectancy in the U.S. has declined significantly over the past few years, falling from 78.8 years in 2019 to 77 in 2020 and 76.1 in 2022 — undoing over two decades of progress.
Big Molecule Watch
NOVEMBER 14, 2023
Regeneron filed a Complaint on November 8 against Celltrion in the U.S. District Court for the Northern District of West Virginia, alleging infringement of thirty-eight patents under the BPCIA based on Celltrion’s submission of an aBLA for CT-P42, a proposed biosimilar of EYLEA (aflibercept), and Celltrion’s provision of Notice of Commercial Marketing with respect to the same.
BioPharma Dive
NOVEMBER 16, 2023
Clearance of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy in the U.K. comes ahead of expected regulatory decisions in the U.S. and Europe.
The Pharmacist
NOVEMBER 16, 2023
All suitably trained members of the pharmacy team will be able to deliver blood pressure checks from 1 December, it has been announced today. And there will be a 'renewed focus' on ambulatory blood pressure monitoring, helping to identify even more people at risk of heart attack and stroke, the pharmacy negotiator said. Currently, under […] The post More pharmacy staff able to deliver blood pressure checks from December appeared first on The Pharmacist.
STAT
NOVEMBER 13, 2023
A small and preliminary study published Monday seems to indicate that patients receiving the drug Paxlovid are far more likely to experience Covid rebound than those who did not take it. That conclusion runs counter to previous statements by Pfizer, which makes Paxlovid, and by researchers at the Food and Drug Administration who have argued that while it is not uncommon for people with Covid to have symptoms reemerge after they seem to have recovered, it is not clear that Paxlovid increases the
PharmExec
NOVEMBER 15, 2023
Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions, capturing the landscape of five expanding therapeutic areas: weight loss, osteoarthritis, Alzheimer’s disease, COPD, and psychedelics.
Pharma Times
NOVEMBER 15, 2023
CHD is a common birth defect that affects the development of the heart and brain - News - PharmaTimes
The Pharmacist
NOVEMBER 15, 2023
The General Pharmaceutical Council (GPhC) fees will increase by 7.5% from April 2024, it has confirmed, following agreement from its council earlier this month. GPhC also defended its decision to have headquarters in London’s Canary Wharf, following calls from members that the organisation should seek to cut its running costs. And the regulator said it […] The post 'Unwelcome' GPhC 7.5% fee increase confirmed appeared first on The Pharmacist.
STAT
NOVEMBER 11, 2023
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss. The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%.
BioPharma Dive
NOVEMBER 13, 2023
Forge Biologics operates a contract manufacturing business as well as develops its own gene therapies, which appears to have attracted the Japan-based food and biotechnology company.
Putting Patients First Blog
NOVEMBER 17, 2023
Guest Post: Five Things You Need to Know About Prediabetes November 17, 2023 By: Robert A. Gabbay, MD, PhD, the ADA’s Chief Science and Medical Officer, American Diabetes Association November is American Diabetes Month® (ADM) at the American Diabetes Association® (ADA). This month often focuses on type 1 and type 2 diabetes. However, prediabetes is also a pressing health concern in the U.S.
The Pharmacist
NOVEMBER 13, 2023
Victoria Atkins has been appointed as the new health secretary in a Cabinet reshuffle, Downing Street has confirmed. Prime Minister Rishi Sunak has appointed the Lincolnshire MP to succeed Steve Barclay in the reshuffle of his top team today. Mr Barclay will stay in the Cabinet as environment, food and rural affairs secretary. Vicky Atkins […] The post Victoria Atkins replaces Steve Barclay as health secretary appeared first on The Pharmacist.
STAT
NOVEMBER 13, 2023
WASHINGTON – The American Medical Association called on insurance companies, employers, and government programs to cover obesity treatments even as many remain reluctant to pay for them, fearing the costs of covering the drugs at a mass scale. The large physicians’ lobbying group voted to pass a resolution at the association’s interim meeting Monday saying it will “urge all payers to ensure coverage parity for evidence-based treatment of obesity, including FDA- approv
Pharma Times
NOVEMBER 16, 2023
The bacteriocin development programme will first target pseudomonas aeruginosa - News - PharmaTimes
BioPharma Dive
NOVEMBER 13, 2023
Trial results add to evidence that so-called Factor XIa inhibitors could have less bleeding risk than currently available oral anticoagulants like Xarelto.
Expert insights. Personalized for you.
109 
Let's personalize your content